Kornimate/medical-research-clean huggingface dataset:
mind body therapy during geriatric rehabilitation

Conditions: Patients Who Are in Need of Short or Long Term Rehabilitation Due to Neurological Event (Mainly Stroke) or Post Orthopedic Surgery

Summary: the main goal of geriatric rehabilitation following an acute illness is rapid restoration of normal activity. the key elements are pain control, restoration of bowel functions, good sleep quality, appetite and general well-being, as well as return to pre illness physical capabilities. emphasis has recently been placed on finding innovative multi-disciplinary methods that can improve the care of elderly people who had suffered an acute illness. the aim of this prospective study is to assess the effect of mind-body therapy(including guided imagery, relaxation techniques, mediation and touch therapy) as as an adjunct to medical and physical rehabilitation in geriatric patients.


Eligibility criteria:
inclusion criteria: 1. inpatients,age 18 and above. 2. getting standard rehabilitation therapy 3. can fill an informed consent. exclusion criteria: 1. medically unstable patients (uncontrolled heart failure,rapid af, severe infection, constant need of oxygen therapy). 2. demented patients who are unable to fill an informed consent

Keywords: rehabilitation mind body therapy integrative medicine
changes in body composition with patients under androgen deprivation therapy

Conditions: Sarcopenia; Prostate Cancer

Summary: this study aimed to evaluate the correlation of change in body composition and oncological outcomes of prostate cancer patients under androgen deprivation therapy(adt).

sarcopenia, decrease lean body mass (lbm) is the well-known parameter which negatively related to physical activity, morbidity and patients survival. aging and decreased blood androgen level are well known risk factors of sarcopenia in male population. androgen deprivation therapy (adt) is commonly performed in advanced or recurred prostate cancer patient and lead to accelerating decreasing blood androgen level. the previous studies defined the sarcopenia after adt by calculated the (muscle component area) / (total body area) on computed tomography (ct) scan. however, ct scan is not recommended for routine follow up examination of adt patients thus this measurement of sarcopenia has limitation on clinical usage. this study using inbody 320 for measure body composition. inbody 320 based on multi-frequency bioelectrical impedance analysis(bia) method that calculated specific body component by differences in impedance indexes of fat, muscle and extracellular body fluid. inbody measurement show precision accuracy and safety on body composition measurement, thus it frequently used in studies of obesity, nutrition and sports fields. we calculating the total skeletal muscle mass (smm), skeletal muscle index(smi), relative skeletal muscle mass index (rasm), fat body mass (fbm), body mass index (bmi), body fat percentage, body water content, and edema value by inbody 320 in the patients who treated by adt in prostate cancer patients. enrolled patients check the body composition parameters at the baseline (before adt) and after adt 3,6,12,18,24 months. we prospectively measuring the 2 years changes of body composition and sarcopenia after adt treatment. patients characteristics (age, underlying disease), prostate cancer status (psa level, gleason grade group, initial treatment), adt methods characters (timing, type) and oncological outcome (recurrence, metastasis, castration resistance) were measuring in the cohort population. post hoc analysis were performed in the timing (initial, salvage or adjuvant) or type (lhrh agonist, antiandrogen or surgical castration) of adt for development of sarcopenia. sub-arm analysis were performed for assessing that effect of presence of sarcopenia on oncological outcome and functional outcomes after adt.

Eligibility criteria:
inclusion criteria: * age over 20 year-old * patient with ecog-ps 0 to 2 * prostate cancer patients * considered androgen deprivation therapy with any cause * patient agreed with informed consent of this study exclusion criteria: * history of previous adt * planned intermittent treatment or short term adt (less than 2 year) * contraindication of adt * severe cognitive impairment, who cannot eligible for survey * secondary malignancy * patient cannot perform inbody test because of physical or underlying disease.

Keywords: androgen deprivation therapy prostate cancer body composition lean body mass
a double blind, placebo controlled trial of quetiapine in anorexia nervosa, a dual site study

Conditions: Anorexia Nervosa

Summary: research studies raise the possibility that medications such as quetiapine may improve mood or reduce obsessions in people with anorexia nervosa and may even help to normalize appetite. the medication quetiapine also known as seroquel works by activating certain systems in the brain, such as ones known as dopamine and serotonin chemical systems in the brain.


Eligibility criteria:
inclusion criteria: * must be aged 18-65 * must be at least 15% below ideal body weight exclusion criteria: * allergy to quetiapine * diagnosis of schizophrenia

Keywords: anorexia nervosa eating disorder study research clinical trial psychiatry psychiatric
preemptive analgesia with morphine sulphate in major urological surgery

Conditions: Pain

Summary: in this study safety and efficacy of oral morphine sulphate is evaluated in order to reduce opioids administration during major urological surgery

the administration of oral morphine sulfate could be useful to reduce the use of opioids in major urological surgery. this study aims to assess the safety and efficacy of two different oral morphine sulphate doses 0,2 mg/kg vs 0,4mg/kg in major urological surgery.

Eligibility criteria:
inclusion criteria: american society of anaesthesiologists physical status classification i/ ii, age between 18 - 75, bmi 18 -30 exclusion criteria: american society of anaesthesiologists physical status classification iii/ iv, renal and hepatic insufficiency, postoperative nausea and vomiting after oral opioids administrations, neurological and psychiatric disorders.

Keywords: premedication oral morphine preemptive analgesia
clinical characteristics and prognosis of aortic dissection in china (classic)

Conditions: Aortic Dissection

Summary: this study will construct a retrospective-prospective long-term follow-up cohort and management system for aortic dissection through a multicentre collaborative network. this study aims to investigate the disease characteristics, progression patterns, clinical features, natural course and factors affecting the disease course and prognosis of patients with aortic dissection by retrospectively collecting data and prospectively enrolling patients.

this study aims to construct a retrospective-prospective long-term follow-up cohort and management system for aortic dissection through a multicentre collaborative network. the duration of the study will be divided into retrospective and prospective components. the retrospective study will collect cases of aortic dissection of different aetiologies from 2003-2022; the prospective study is expected to collect cases of aortic dissection from 2022-2030. the study is expected to assess the disease characteristics, progression patterns, clinical features, natural course and long-term prognosis of aortic coarctation.

Eligibility criteria:
inclusion criteria: * age 18-80 years; * meet diagnostic criteria for aortic dissection. exclusion criteria: * age \ 80 years; * women who are pregnant and breastfeeding; * patients and their families refuse or are unable to sign the informed consent form.

Keywords: aortic dissection clinical characteristics prognosis
atmospheric projection in the emergency department

Conditions: Pain, Acute; Anxiety Acute

Summary: the goal of this clinical trial is to learn about the reduction of pain and anxiety during a minor procedure in the emergency department on adult patients through the visualisation of atmospheric projection as a distraction mean. the main question it aims to answer is : can the atmospheric projection of a video reduce pain and anxiety in adult patients receiving painful procedures in the emergency department ? participants will look at an atmospheric projection (projection of a media on the walls and roof around the patient) while receiving their planned care procedures. researchers will compare an active group watching a video with a control group watching a simple colored light to see if the visualisation of an atmospheric projected video reduces pain and anxiety more than the visualisation of a colored light does.


Eligibility criteria:
inclusion criteria: * aged ≥18 ; * patient requiring one of the following treatment procedures : suturing, plaster cast placement and/or repositioning, fracture or dislocation reduction, ascites puncture, pleural puncture, lumbar puncture. exclusion criteria: * patient clinically unstable; * patient incapable of discernment or consent ; * altered mental status (cognitive disorders, mental retardation, acute state of confusion, acute psychosis); * alcoholic patient with university of california, san diego brief assessment of capacity to consent (ubacc) score of 10/10 ; * patient hard of hearing ; * patient with visual impairments preventing him/her from perceiving his/her environment ; * patient unable to understand the use of visual analog scales (vas); * impaired sensitivity of the part of the body where the medical intervention is to take place; * planned use of analgesia/sedation with a dissociative agent (midazolam, ketamine, propofol); * incarcerated patient ; * patient transferred from another hospital ; * patient having already participated in this study during a previous consultation in the emergency department of the centre hospitalier universitaire vaudois.
heart rate variability as a predictor of ischemic heart disease

Conditions: Acute Coronary Syndrome

Summary: identification of patients who are at highest risk for heart attack is an important task for emergency medicine physicians. currently, physicians use a variety of different scoring systems to stratify their risk for having a heart attack. heart rate variability (hrv) is a measure derived from noninvasive cardiac monitoring. this data is collected from a simple, non-invasive chest strap during a 10-minute recording session. the purpose of this proposal is to collect heart rate variability data on patients admitted to the emergency department with chest pain. the intent is to measure the association between heart rate variability and the various risk stratification scoring systems for chest pain.

identification of patients who are at highest risk for heart attack is an important task for emergency medicine physicians. currently, physicians use a variety of different scoring systems to stratify their risk for having a heart attack. heart rate variability (hrv) is a measure derived from noninvasive cardiac monitoring. this data is collected from a simple, non-invasive chest strap during a 10-minute recording session. the purpose of this proposal is to collect heart rate variability data on patients admitted to the emergency department with chest pain. the intent is to measure the association between heart rate variability and the various risk stratification scoring systems for chest pain. the investigators propose to enroll patients admitted to the emergency department with chest pain. in addition to hrv data, clinical risk factors will be obtained, using validated clinical risk scoring systems. the team will follow patient's clinical course in order to include information about the determined cause of chest pain. the goal is to understand how hrv can augment common risk stratification scoring systems for patient presenting to the ed with chest pain.

Eligibility criteria:
inclusion criteria: * chest pain in ed exclusion criteria: * stemi * prisoners * pregnant women * unable to consent

Keywords: heart rate variability
evaluation of platelet aggregability in patients with takayasu's arteritis

Conditions: Takayasu Arteritis (TAK); Vasculitis, Systemic

Summary: inflammatory syndromes in general, and primary vasculitis specifically, present a high risk of cardiovascular involvement. takayasu arteritis (tak), for example, presents cardiovascular complications in up to 60% of cases. it is a systemic inflammatory disease that primarily affects large vessels, such as the aorta and its main branches. from a pathophysiological point of view, there are several causes that can lead to an exacerbated increase in cardiovascular risk in this population, including accelerated atherosclerosis, pro-inflammatory action of platelets and significant endothelial dysfunction. in this context, the present case-control study intends to include 100 individuals (50 with tak - case group, and 50 healthy volunteers - control group), matched by age and sex in a 1:1 ratio. the main objective of the study is to compare platelet aggregability in patients with tak against healthy volunteers using the aggram® test. among its secondary objectives is the analysis of platelet aggregability by other methods (plateletworks, chronolog, and ppanalysis). the study aims to significantly contribute to a better understanding of the potential influence of tak on platelet aggregation and the response to antiplatelet agents, thereby contributing to a better understanding of the disease, with evident prognostic and therapeutic implications.


Eligibility criteria:
inclusion criteria: * patients with tak, according to the acr/eular 2022 classification criteria (score ≥ 5 out of a total of 20 points) \[17\] * age \> 18 years * using acetylsalicylic acid * agreement to sign the free and informed consent form (tcle). exclusion criteria: * previous hemorrhagic stroke * use of another antiplatelet agent other than acetylsalicylic acid * active infection or current use of systemic antimicrobial therapy * known platelet dysfunction or platelets \ 450,000/µl * severe illness with life expectancy ≤12 months * known liver disease or coagulation disorder * abuse of illicit drugs or alcohol * dementia, psychiatric condition or any condition that, in the researcher's opinion, prevents participation and follow-up in the protocol

Keywords: platelets platelet aggregation optical aggregometry
pain and fear of venous blood collection in children

Conditions: Pain; Fear

Summary: nurses are in the position of primary health care provider in relieving children's pain and fears of bloodletting in the wards where they work. as a result of this study, it is aimed to encourage nurses to apply non-pharmacological interventions during painful medical procedures, to facilitate the provision of necessary and different means of distraction to blood collection services, and to contribute to the development of in-house health policies and the preparation of appropriate clinical guides and to add an innovative perspective.


Eligibility criteria:
inclusion criteria: * 6-12 age group, * children who need blood drawn for any reason * have no disease that can cause chronic pain, * no olfactory disorder * no mental or neurological problems * able to communicate * speaks turkish exclusion criteria: * those who did not give consent to the research by both the child and the parent
safety and feasibility of liver retraction with the levita magnetic surgical system: extended magnetic grasper device

Conditions: Bariatric Surgery Candidate; Hiatal Hernia

Summary: the purpose of this study is to evaluate the safety and effectiveness of the extended magnetic grasper device in patients undergoing bariatric and/or hiatal hernia procedures, as a liver retractor grasping the liver and/or the tissue surrounding the crus of the diaphragm.

the purpose of this study is to evaluate the safety and effectiveness of the levita magnetic surgical system version 2 in patients undergoing bariatric and/or hiatal hernia procedures.

Eligibility criteria:
inclusion criteria: * at least 18 years of age. * scheduled to undergo elective bariatric and/or hiatal hernia procedures. * willing and able to provide a written informed consent form (icf) to participate in the study prior to any study required procedures. exclusion criteria: * individuals with pacemakers, defibrillators, or other electromedical implants. * individuals with ferromagnetic implants. * american society of anesthesiologists (asa) score of iii or iv. * significant comorbidities: cardiovascular, neuromuscular, chronic obstructive pulmonary disease, and urological disease (renal failure). * clinical history of impaired coagulation confirmed by abnormal blood tests. * individuals has signs of hepatic abnormality (e.g.: cirrhosis, liver failure, increase in liver enzymes, etc.). * anatomical abnormality or disease of intended target tissue noted after initiation of index procedure that would prevent device use. * pregnant or wishes to become pregnant during the length of study participation. * individual is not likely to comply with the follow-up evaluation schedule. * participating in a clinical trial of another investigational drug or device. * prisoner or under incarceration.
prenatal multi-micronutrient supplementation and pregnancy outcome

Conditions: Pregnancy; Birth Weight

Summary: prenatal maternal micronutrient supplementation has been suggested as a means to reduce the proportion of low birth weight babies in low-income countries. the effects of prenatal multi-micronutrient supplements on birth weight and perinatal mortality were studied in a randomised controlled trial among 2100 pregnant women in guinea-bissau. women up to 37 weeks pregnant were individually randomised to daily supplements until delivery of a) iron + folic acid or multi-micronutrients in b) one or c) two recommended dietary allowances. secondary outcomes were infant growth and maternal haemoglobin eight weeks after delivery.

prenatal maternal micronutrient supplementation has been suggested as a means to reduce the proportion of low birth weight babies in low-income countries. the effects of prenatal multi-micronutrient supplements on birth weight and perinatal mortality were studied in a randomised controlled trial among 2100 pregnant women in guinea-bissau. women up to 37 weeks pregnant were individually randomised to daily supplements until delivery of identically looking tablets containing 1) iron (60 mg) + folate (400 µg), 2) one recommended dietary allowance (rda) of 5 minerals and 10 vitamins, including iron (30 mg) and folate (400 µg), or 3) two rda's of 5 minerals and 10 vitamins, including iron (30 mg) and folate (800 µg). supplements were provided in known excess at fortnightly home visits until delivery. compliance was assessed by tablet count. women were interviewed about age, civil status, obstetric history and socio-economic status at enrolment. maternal anthropometry was measured at enrolment, at delivery, and eight weeks after delivery. maternal malaria parasitaemia and haemoglobin were measured at enrolment and eight weeks after delivery. maternal status of a wide range of micronutrients was assessed at enrolment and eight weeks after delivery in a sub-cohort of 600 women. further, survival of the infants will be followed until 3 years of age, within the routines of the bandim health project surveillance system. women were provided impregnated bed nets and weekly malaria prophylaxis until delivery. women with high malaria parasitaemia at enrolment were in addition given a full treatment at enrolment. sample size considerations: a sample size of 638 women in each treatment group will be required to detect a reduction in perinatal mortality from 9% to 5% or less in a treatment group using 80% power and a 5% significance level. with an expected loss to follow up of 10%, 2100 women are required. with a sample size of 2100 the study will be able to detect at least 75 g difference, i.e. a 2.5% change in birth weight.

Eligibility criteria:
inclusion criteria: * pregnant women exclusion criteria: * \>37 weeks of gestational at enrollment

Keywords: micronutrient supplementation pregnancy birth weight perinatal mortality
lifestyle guidance methods in nafld

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: to determine the efficiency of lifestyle modification (due to a dietitian or digital application) compared to standard of care.


Eligibility criteria:
inclusion criteria: * nafld based in fibroscan measurements exclusion criteria: * excessive alcohol use * other causes of liver disease * secondary causes of liver steatosis
a study of ak131 in patients with advanced solid tumors

Conditions: Solid Tumor

Summary: this is a phase ia/ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ak131 in advanced solid tumor patients


Eligibility criteria:
inclusion criteria: 1. written and signed informed consent. 2. eastern cooperative oncology group (ecog) performance score of 0 or 1. 3. life expectancy ≥3 months. 4. histologically or cytologically documented unresectable advanced or metastatic malignant tumor that has failed or intolerant of standard therapy, or for which no effective standard therapy is available. 5. subject must have at least one measurable lesion according to recist version1.1. 6. adequate organ function. 7. female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective barrier methods of contraception during the study and for 120 days after last dose of study drug. exclusion criteria: 1. any malignancy other than the disease under study within the past 3 years except for radically cured local cancers. 2. being involved in another clinical study, except for observational clinical studies or follow-up period of interventional studies. 3. receipt of any anti-cd73 treatment. 4. anticancer therapy within 4 weeks prior to the first dose of investigational product. 5. experienced a toxicity that led to permanent discontinuation of prior immunotherapy. 6. subjects with spinal cord compression or active brain metastases, except for subjects with untreated and asymptomatic brain metastases or with stable brain metastases after treatment. 7. subjects with pleural effusion, pericardial effusion, or ascites requiring repeated drainage. 8. subjects whose imaging shows that the tumor has invaded important blood vessels or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal bleeding during the study. 9. toxicities of prior anticancer therapy have not resolved to ≤ grade 1. 10. patients with clinically significant cardio-cerebrovascular disease. 11. active autoimmune diseases or history of autoimmune diseases that may relapse. 12. history of interstitial lung disease or noninfectious pneumonitis. 13. major surgery, trauma,unhealed wound, ulcer or fracture within 4 weeks prior to first dose of investigational product. 14. any condition that required systemic treatment with corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of investigational product. 15. receipt of live attenuated vaccines within 4 weeks prior to the first dose of investigational product. 16. known allergy or reaction to any component of the ak131 formulation. 17. previous organ transplantation or allogeneic hematopoietic stem cell transplantation. 18. any other conditions that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.